The purpose of this clinical trial is to evaluate the safety and efficacy of rhEGF (recombinant human Epidermal Growth Factor) in diabetic foot ulcer patients with uncontrolled diabetes mellitus.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
176
College of Medicine, Yonsei University
Seoul, South Korea
At 12 weeks, wound closure rate of diabetic foot ulcers
Time frame: 12 weeks from the start day of treatment (But, the study can be finished before 12 weeks)
Time to reach complete wound closure
Time frame: 12weeks
average size reduction of diabetic ulcer
Time frame: 12 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.